Search
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.
Categories: MATE 1 Inhibitors, Heterocyclic Compounds, 1-RingProducts: TUKYSA 50 mg film-coated tablets, TUKYSA (TUCATINIB) FILM-COATED TABLETS 50 mgMagaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Mixtures: M A L D I M, ASIDOPAN PLUS 200 ML SUSPANSIYONCategories: Alimentary Tract and Metabolism, magaldrate and antiflatulentsSevelamer
go.drugbank.com/drugs/DB00658ApprovedInvestigationalSevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Categories: Drugs for Treatment of Hyperkalemia and Hyperphosphatemia, Compounds used in a research, industrial, or household settingProducts: <html>RENALAMER CO<sub>3</sub> 800 MG FILM TABLET, 180 ADET</html>, RENVELA 2,4 G ORAL SÜSPANSIYON IÇIN TOZ, 60 SAŞERavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [L39690,L39700] Ravulizumab is currently being investigated for the treatment of Coronavirus disease (COVID-19)-induced microvasculature injury and endothelial damage leading to thrombotic microangiopathy
Categories: Complement C5 inhibitors, Amino Acids, Peptides, and ProteinsProducts: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.Aluminum acetate
go.drugbank.com/drugs/DB14518ApprovedInvestigationalMixtures: ZISUAL-C, SPERTI PREPARATION HProducts: ACETATO DE ALUMINIO 15 MG/100 ML SOLUCION TOPICA, ACETATO DE ALUMINIO 0.118G/100 MLMedazepam
go.drugbank.com/drugs/DB13437InvestigationalMixtures: TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 40 ADET, TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 20 ADETCategories: Heterocyclic Compounds, 2-Ring, Hypnotics and SedativesDiazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigationalIn September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates. … Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxideCreatinine Clearance 5-15 mL/min
go.drugbank.com/conditions/DBCOND0133572Drugs: Amino acidsSynonyms: Creatinine Clearance 5-15 mL/minPentosan polysulfate
go.drugbank.com/drugs/DB00686ApprovedInvestigationalPentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties.
Synonyms: (4-O-METHYL-.ALPHA.-D-GLUCURONO)-(1->2)-(1->4)-.BETA.-D-XYLOPYRANAN, HYDROGEN SULFATE, (4-O-METHYL-.ALPHA.-D-GLUCURONO)-(1->2)-(1->4)-.BETA.-D-XYLOPYRANAN, HYDROGEN SULPHATECategories: Heparin and similars, Genito Urinary System and Sex HormonesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.
Categories: Antineoplastic and Immunomodulating Agents, Cytochrome P-450 SubstratesProducts: RİNVOQ 15 MG UZATILMIŞ SALIMLI TABLET, 98 ADET, RİNVOQ 15 MG UZATILMIŞ SALIMLI TABLET, 28 ADET